



MEDICAL DEVICES



PHARMACEUTICALS



CHEMICALS



FOOD & BEVERAGE



ELECTRONICS

*Available fo Immediate Delivery !*

# 2009-2018 **THREE ALTERNATIVE SCENARIOS** of The Future In Vitro Diagnostics Market

DESIGNED TO HELP INDUSTRY EXECUTIVES DEVELOP EFFECTIVE CONTINGENCY PLANS THAT BEST ACCOMMODATE UNCERTAINTIES AHEAD.

Scenario I: Business-As-Usual

Scenario II: Economic Austerity

Scenario III: Technological Breakthroughs

*Visit [www.vpgcorp.com](http://www.vpgcorp.com) to review this and over 5,000 other reports*



VENTURE PLANNING GROUP

[WWW.VPGCORP.COM](http://WWW.VPGCORP.COM)

INFORMATION • INTELLIGENCE • ANALYSIS • INSIGHT

# Table of Contents

## I. INTRODUCTION

## II. EXECUTIVE SUMMARY

### A. BUSINESS-AS-USUAL SCENARIO

### B. ECONOMIC AUSTERITY SCENARIO

### C. TECHNOLOGICAL BREAKTHROUGHS SCENARIO

## III. CONCLUSIONS AND RECOMMENDATIONS

## IV. THE SCENARIOS, 2006-2016

### A. BUSINESS-AS-USUAL SCENARIO

#### 1. Business Environment

##### a. Health Care Expenditures

##### b. Cost-Consciousness

##### c. Reimbursement

##### d. Industry Consolidation

##### e. Managed Care

- PPOs

- HMOs

##### f. Hospitals

##### g. Admissions

##### h. Length of Stay

##### i. Industry Diversification

##### j. Physician Demographics

##### k. Aging Population

- Chronic Illnesses

- Disease Incidence

- Susceptibility to Iatrogenesis

- Multiple Illness Cases

##### l. Laboratory Regulations

##### m. The FDA Reform

#### 2. Outlook for the In Vitro Diagnostics Market

##### a. Government Regulations

##### b. Centralized Testing

- Hospitals

- Commercial Laboratories

- Blood Banks

- Public Health Laboratories

##### c. Decentralized Testing

- Personal Testing

- Physician Offices/Group Practices

- Ancillary Hospital Locations

- ERs

- ORs

- ICUs/CCUs

- Cancer Clinics

- Ambulatory Care Centers

- Surgery Centers

- Nursing Homes

- Birth Centers

#### 3. Strategic Implications

##### a. Testing Patterns

- Test Utilization

- Pre-Admission Testing

- Inpatient Testing

- Outpatient Testing

#### 4. Market Segments

##### a. Chemistry and Immunoassay

- Introduction

- Future Situation

##### b. Microbiology and Serology

- Introduction

- Future Situation

##### c. Hematology and Flow Cytometry

- Introduction

- Future Situation

##### d. Histology and Cytology

- Introduction

- Future Situation

##### e. Coagulation

- Introduction

- Future Situation

##### f. Urinalysis

- Introduction

- Future Situation

##### g. Blood Banking

- Introduction

- Future Situation

## 5. Technologies

### a. Genomics

- Introduction

- Future Situation

### b. Proteomics

- Introduction

- Future Situation

### c. DNA Probes

- Introduction

- Future Situation

### d. Biochips/Microarrays

- Introduction

- Future Situation

### e. Monoclonal Antibodies

- Introduction

- Future Situation

### f. Solid Phase Chemistry

- Introduction

- Future Situation

### g. Biosensors

- Introduction

- Future Situation

### h. Automation and Robotics

- Introduction

- Future Situation

### i. Computer-Aided Diagnosis

- Introduction

- Future Situation

## 6. The New Marketplace

### a. Purchasing Influences

### b. Marketing Strategies

### c. Joint Ventures, Mergers and Licensing

### d. Import-Export

### e. Potential Market Entrants

### f. Who May Not Survive?

## B. ECONOMIC AUSTERITY SCENARIO

### 1. Business Environment

#### a. Socio-Political Climate

- Cost-Consciousness

- Government Actions

- Three-Tier System

- Health Rationing

- Voucher System

- Health IRA

#### b. Hospital Closures

#### c. Hospital Utilization

#### d. Hospital Reorganization

#### e. Physician Regulations

#### f. Wellness Programs

#### g. Corporate Responses

#### h. Academic Research

### 2. Outlook for the In Vitro Diagnostics Market

#### a. Test Utilization

- Ordering Practices

- Documentation

- Recertification

#### b. Technology Regulations

#### c. New Laboratory Ventures

#### d. Computers

#### e. Industrial Medicine

#### f. Insurance Companies

#### g. Test Volume and Market Size

### 3. Strategic Implications

#### a. Testing Patterns

- Pre-Admission Testing

- Inpatient Testing

- Outpatient Testing

#### b. Market Segments

- Chemistry and Immunoassay

- Microbiology and Serology

- Hematology and Flow Cytometry

- Histology and Cytology

- Coagulation

- Urinalysis

- Blood Banking

## c. Technologies

- Genomics

- Proteomics

- DNA Probes

- Biochips/Microarrays

- Monoclonal Antibodies and Immunoassays

- Automation and Robotics

- Solid Phase Chemistry

- Biosensors

- Computer-Aided Diagnosis

## d. The New Marketplace

- Purchasing Influences

- Marketing Strategies

- Joint Ventures, Mergers and Licensing

- Import-Export

- Potential Market Entrants

- Who May Not Survive?

## C. TECHNOLOGICAL BREAKTHROUGHS SCENARIO

### 1. Business Environment

#### a. Political/Regulatory Climate

#### b. R & D Funding

#### c. Industry-Government Relationship

#### d. Industry-University Ventures

#### e. Technological Environment

#### f. Testing Decentralization

#### g. Health Care Expenditures

#### h. Physician Population

#### i. Hospital Indicators

### 2. Outlook for the In Vitro Diagnostics Market

#### a. Overview

#### b. Genomics

#### c. Proteomics

#### d. DNA and RNA Probes

#### e. Biochips/Microarrays

#### f. Monoclonal Antibodies

#### g. Immunoassays

#### h. Information Technology

#### i. Laboratory Automation and Robotics

#### j. Solid Phase Chemistry

#### k. Biosensors

#### l. Holography

#### m. Pharmaceuticals

### 3. Strategic Implications

#### a. Testing Patterns

- Pre-Admission Testing

- Inpatient Testing

- Outpatient Testing

- Test Volume and Market Size

#### b. Market Segments

- Chemistry and Immunoassay

- Microbiology and Serology

- Hematology and Flow Cytometry

- Histology and Cytology

- Coagulation

- Urinalysis

- Blood Banking

#### c. The New Marketplace

- Purchasing Influences

- Marketing Strategies

- Joint Ventures, Mergers and Licensing

- Import-Export

- Potential Market Entrants

- Who May Not Survive?

## V. APPENDICES: METHODOLOGY

### A. The Delphi

### B. Cross-Impact Analysis

### C. Substitution Modeling

# List of Tables

**Executive Summary Table I:** Business-As-Usual Scenario, Growth Areas in Clinical Laboratory Testing, 2008-2018

**Executive Summary Table II:** Economic Austerity Scenario, Growth Areas in Clinical Laboratory Testing, 2008-2018

**Executive Summary Table III:** Technological Breakthroughs Scenario, Growth Areas in Clinical Laboratory Testing, 2008-2018

**Executive Summary Table IV:** Market Size by Location

**Executive Summary Table V:** Market Size by Laboratory Discipline

**Table-1:** Business-As-Usual Scenario, Health Care Costs by Expenditure Type

**Table-2:** Business-As-Usual Scenario, HMO and PPO Enrollment

**Table-3:** Business-As-Usual Scenario, Selected Hospital Statistics

**Table-4:** Business-As-Usual Scenario, Total Population and Physician Demographics

**Table-5:** Business-As-Usual Scenario, Test Volume by Location

**Table-6:** Business-As-Usual Scenario, Test Distribution by Location

**Table-7:** Business-As-Usual Scenario, Market Size by Location

**Table-8:** Business-As-Usual Scenario, Typical Pre-Admission Tests

**Table-9:** Business-As-Usual Scenario, Test Volume by Laboratory Discipline

**Table-10:** Business-As-Usual Scenario, Market Size By Laboratory Discipline

**Table-11:** Economic Austerity Scenario, Selected Hospital Statistics

**Table-12:** Economic Austerity Scenario, HMO and PPO Enrollment

**Table-13:** Economic Austerity Scenario, Total Population and Physician Demographics

**Table-14:** Economic Austerity Scenario, Major Categories of Overutilized Tests

**Table-15:** Economic Austerity Scenario, Test Volume by Location

**Table-16:** Economic Austerity Scenario, Test Distribution by Location

**Table-17:** Economic Austerity Scenario, Market Size by Location

**Table-18:** Economic Austerity Scenario, Timing Requirements for Selected Laboratory Tests

**Table-19:** Economic Austerity Scenario, Test Volume by Laboratory Discipline

**Table-20:** Economic Austerity Scenario, Market Size by Laboratory Discipline

**Table-21:** Technological Breakthroughs Scenario, HMO and PPO Enrollment

**Table-22:** Technological Breakthroughs Scenario, Total Population and Physician Demographics

**Table-23:** Technological Breakthroughs Scenario, Selected Hospital Statistics

**Table-24:** Technological Breakthroughs Scenario, Test Volume by Location

**Table-25:** Technological Breakthroughs Scenario, Test Distribution by Location

**Table-26:** Technological Breakthroughs Scenario, Market Size by Location

**Table-27:** Technological Breakthroughs Scenario, Test Volume by Laboratory Discipline

**Table-28:** Technological Breakthroughs Scenario, Market Size by Laboratory Discipline